A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

Inclusion Criteria:

• Have a definite clinical diagnosis of stable (at least 6 months) plaque psoriasis,involving at least 2% and no more than 20% of the body surface area (BSA) (notincluding the scalp and intertriginous areas)

• Have a minimum plaque elevation at the target lesion site of at least moderateseverity (grade ≥ 3 on the Psoriasis Area Severity Index [PASI]). The most severelesion at baseline should be identified as the target lesion

• Have an Investigator's Global Assessment (IGA) of disease severity of at leastmoderate (score ≥ 3) as an overall assessment of all lesions to be treated.

Exclusion Criteria:

• A female subject who is pregnant, nursing, planning a pregnancy, or does not agree touse an acceptable form of birth control within the study participation period

• Have a current diagnosis of unstable forms of psoriasis in the treatment area,including pustular, guttate, exfoliative or erythrodermic psoriasis

• Have a history of psoriasis unresponsive to topical treatments